SuperworthNovoCure profit margin NVCR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- −21.2%
- Operating margin, 12 months
- −22.1%
- Net margin on a year earlier
- +5.9 pts
- Peer median
- 7.3%
Over the twelve months to Jun 30, 2026, NovoCure kept −21.2% of its revenue as net profit, with an operating margin of −22.1% and a gross margin of 76.1%.
Five years earlier its net margin was −0.8%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −20.8% | −23.5% | 74.5% |
| FY2024 | −27.9% | −28.2% | 77.3% |
| FY2023 | −40.6% | −45.7% | 74.8% |
| FY2022 | −17.2% | −16.6% | 78.6% |
| FY2021 | −10.9% | −8.3% | 78.5% |
| FY2020 | 4.0% | 6.1% | 78.5% |
| FY2019 | −2.1% | −0.3% | 74.8% |
| FY2018 | −25.6% | −13.6% | 67.7% |
| FY2017 | −34.8% | −22.2% | 68.6% |
| FY2016 | n/a | n/a | 44.2% |
| FY2015 | n/a | n/a | 37.7% |
| FY2014 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −21.2% | +5.9 pts | −22.1% | |
| Q1 FY26 | −25.7% | +0.8 pts | −27.2% | |
| Q4 FY25 | −20.8% | +7.1 pts | −23.5% | |
| Q3 FY25 | −27.7% | −1.7 pts | −27.5% | |
| Q2 FY25 | −27.1% | +3.5 pts | −27.4% | |
| Q1 FY25 | −26.4% | +10.3 pts | −26.8% | |
| Q4 FY24 | −27.9% | +12.8 pts | −28.2% | |
| Q3 FY24 | −25.9% | +13.2 pts | −27.5% | |
| Q2 FY24 | −30.7% | +3.7 pts | −33.6% | |
| Q1 FY24 | −36.7% | −9.7 pts | −40.7% | |
| Q4 FY23 | −40.6% | −23.4 pts | −45.7% | |
| Q3 FY23 | −39.1% | −24.1 pts | −44.5% |
Against its peers
Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.
| Company | Profit margin |
|---|---|
| NVCRNovoCure | −21.2% |
| LMATLemaitre Vascular | 25.0% |
| EYENational Vision | 2.5% |
| INSPInspire Medical Systems | 15.0% |
| CDRECadre | 5.3% |
| UFPTUFP Technologies | 11.4% |
| BVSBioventus | 9.4% |
| STAAStaar Surgical | 1.1% |
| IRMDIradimed | 26.7% |
| ATRCAtriCure | 1.9% |
| WRBYWarby Parker | 0.8% |
| Peer median | 7.3% |
Where NovoCure ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on NovoCure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.